AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Revelation Biosciences Adjourns Oct 15 Special Meeting to Oct 29
ByAinvest
Wednesday, Oct 15, 2025 5:12 pm ET1min read
Revelation Biosciences has adjourned its 2025 Special Meeting of Stockholders due to insufficient shares present. The meeting will reconvene on October 29, 2025, at 12:00 p.m. Eastern Time, and will be held virtually via webcast. The record date for the meeting remains September 11, 2025. The Company is focused on rebalancing inflammation and is a clinical-stage life sciences company.
Revelation Biosciences, Inc. (NASDAQ:REVB), a clinical-stage life sciences company focused on rebalancing inflammation, has announced the adjournment of its 2025 Special Meeting of Stockholders. Originally scheduled for October 15, 2025, the meeting was adjourned due to insufficient shares present and will reconvene on October 29, 2025, at 12:00 p.m. Eastern Time. The meeting will continue to be held virtually via webcast.
The record date for the meeting remains unchanged at September 11, 2025. Stockholders who have already voted do not need to take any further action unless they wish to change their votes. Those who have not yet voted are encouraged to do so before the new meeting date by following the instructions provided in the company's proxy materials.
The company strongly encourages all stockholders, regardless of the number of shares they hold, to participate in the meeting and exercise their right to vote as soon as possible. Additional information regarding the meeting and voting procedures is available in the company's proxy statement filed with the U.S. Securities and Exchange Commission and summarized in a
.Revelation Biosciences is a clinical-stage biotechnology company pioneering immunologic therapeutics through its proprietary Gemini platform. The company's therapeutic pipeline includes Gemini-SSI (surgical infection prevention), Gemini-AKI (acute kidney injury), and Gemini-CKD (chronic kidney disease) programs. The company has recently announced significant warrant exercise agreements and positive clinical trial results, highlighting its progress in inflammation modulation, according to
.Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet